# Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]

> **NCT03747120** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 138 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03747120
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-25
- **Primary completion:** 2024-11-08
- **Final completion:** 2029-12
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03747120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03747120, "Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03747120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*